R T Osteen
- Cancer Research top 5%
- Breast Cancer Treatment Studies 6
-
- Lymphoma Diagnosis and Treatment 4
- Genetic factors in colorectal cancer 2
-
- Occupational and environmental lung diseases 4
- Oncology top 10%
- Vascular Tumors and Angiosarcomas 2
- Cancer Treatment and Pharmacology 2
- Cancer Diagnosis and Treatment 2
- Hepatology top 10%
- Hepatocellular Carcinoma Treatment and Prognosis 2
R T Osteen
19 papers receiving 1.2k citations
Peers
Comparison fields: 5 of 69
- Cancer Research 385
- Pathology and Forensic Medicine 442
- Pulmonary and Respiratory Medicine 516
- Oncology 406
- Hepatology 85
Countries citing papers authored by R T Osteen
This map shows the geographic impact of R T Osteen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R T Osteen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R T Osteen more than expected).
Fields of papers citing papers by R T Osteen
This network shows the impact of papers produced by R T Osteen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R T Osteen. The network helps show where R T Osteen may publish in the future.
Co-authorship network
The 25 scholars most cited alongside R T Osteen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma. | 2000 | 24 |
| 2 | 1996 | 29 | |
| 3 | 1995 | 8 | |
| 4 | 1995 | 2 | |
| 5 | 1991 national survey of carcinoma of the breast by the Commission on Cancer. | 1994 | 78 |
| 6 | 1994 | 55 | |
| 7 | 1993 | 10 | |
| 8 | Preoperative irradiation for unresectable carcinoma of the rectum. | 1993 | 11 |
| 9 | 1992 | 65 | |
| 10 | Recurrence in the breast following conservative surgery and radiation therapy for early-stage breast cancer. | 1992 | 51 |
| 11 | 1991 | 213 | |
| 12 | 1991 | 2 | |
| 13 | 1990 | 82 | |
| 14 | 1988 | 133 | |
| 15 | 1988 | 232 | |
| 16 | Combined modality treatment of peritoneal mesotheliomas. | 1988 | 4 |
| 17 | 1985 | 67 | |
| 18 | 1983 | 81 | |
| 19 | 1983 | 63 |
About R T Osteen
R T Osteen is a scholar working on Cancer Research, Oncology and Pathology and Forensic Medicine, having authored 19 papers that have together received 1.2k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (6 papers), Occupational and environmental lung diseases (4 papers), Lymphoma Diagnosis and Treatment (4 papers), Vascular Tumors and Angiosarcomas (2 papers), Hepatocellular Carcinoma Treatment and Prognosis (2 papers), Genetic factors in colorectal cancer (2 papers), Cancer Treatment and Pharmacology (2 papers) and Cancer Diagnosis and Treatment (2 papers). The work is most often cited by research in Cancer Research (385 citations), Pathology and Forensic Medicine (442 citations) and Pulmonary and Respiratory Medicine (516 citations). R T Osteen has collaborated with scholars based in United States. Frequent co-authors include Barbara Silver, David P. Winchester, G Steele, Anthony Abner, Frank A. Vicini, Abram Recht, Richard J. Shemin, Karen H. Antman, Gilbert S. Lederman and Tessa Herman. Their work appears in journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.